Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.35 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.35 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799196 | 1.00 | CYP1A2 (0.43) | CYP1A2TDP1TSHRMAPTPOLB | |
| SCHEMBL357615 | 1.00 | CYP1A2 (0.43) | CYP1A2TDP1TSHRMAPTPOLB | |
| SCHEMBL9446411 | 0.83 | TSHR (0.39) | CYP1A2TDP1TSHRMAPTGAA | |
| SCHEMBL4248088 | 0.83 | TSHR (0.39) | CYP1A2TDP1TSHRMAPTGAA | |
| SCHEMBL3829548 | 0.83 | TSHR (0.39) | CYP1A2TDP1TSHRMAPTGAA | |
| Hydrochloric Acid SCHEMBL4246521 | 0.81 | TSHR (0.38) | CYP1A2TDP1TSHRMAPTGAA | |
| SCHEMBL16009685 | 0.81 | TSHR (0.38) | CYP1A2TDP1TSHRMAPTGAA | |
| Hydrochloric Acid SCHEMBL21805904 | 0.81 | TSHR (0.38) | CYP1A2TDP1TSHRMAPTGAA | |
| SCHEMBL21885560 | 0.81 | TSHR (0.38) | CYP1A2TDP1TSHRMAPTGAA | |
| SCHEMBL16009686 | 0.81 | TSHR (0.38) | CYP1A2TDP1TSHRMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023020457-A1 | PYRIDAZINONE OR PYRIDINONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-02-23 | — | — | WO | disclosed |
| US-10227359-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180222920-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2018-08-09 | — | — | US | disclosed |
| US-9834565-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170158710-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2017-06-08 | — | — | US | disclosed |
| EP-2336132-B1 | MORPHOLINOPURINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2014-01-01 | — | — | EP | disclosed |
| US-8309546-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8022059-B2 | Indazole acrylic acid amide compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-20 | — | — | US | disclosed |
| EP-2336132-A1 | MORPHOLINOPURINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20100256108-A1 | INDAZOLE ACRYLIC ACID AMIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227359-B2 | Tricyclic heterocycles as bet protein inhibitors | BRD3, BRD1, BRD2 | CYP1A2 4101/4885TDP1 981/4885TSHR 1954/4885 |
| US-20170158710-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD3, BRD1, BRD2 | CYP1A2 4101/4885TDP1 981/4885TSHR 1954/4885 |
| US-20180222920-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD3, BRD1, BRD2 | CYP1A2 4101/4885TDP1 981/4885TSHR 1954/4885 |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | CYP1A2 3323/4885TDP1 1498/4885TSHR 2037/4885 |
| US-20100256108-A1 | INDAZOLE ACRYLIC ACID AMIDE COMPOUND | KCNH2, KCNH3, KCNJ11 | CYP1A2 607/4885TDP1 4376/4885TSHR 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.